MoonLake Immunotherapeutics shares surged 31% after the Financial Times reported, citing unnamed sources, that the company had rejected an initial acquisition offer by Merck & Co. for more than $3 ...

Wall Street gains as S&P 500 surpasses 6,000; key healthcare stock movers revealed. Explore top deals, trends, and regulatory updates in the sector.

Abdominal obesity is a greater risk factor for psoriasis than total body fat, according to an analysis of imaging data, ...

Detailed price information for Keros Therapeutics Inc (KROS-Q) from The Globe and Mail including charting and trades.

MoonLake jumps 18% after a report says MRK made a $3 billion-plus offer earlier this year, with talks potentially set to resume.

Investors are swarming AbbVie with bullish bets, as call options surged past expectations and sent volatility ticking up.

Stocks closed higher on Tuesday as the Nasdaq Composite finished the day higher for the year even as uncertainty over global ...

MoonLake Immunotherapeutics' Sonelokimab's Phase 3 trials, PsA market growth, and Merck's $3B bid showcase potential. Read my ...

MERCK has held talks to buy Swiss biotech MoonLake Immunotherapeutics for more than $3 billion, the Financial Times (FT) reported on Monday, citing three people familiar with the matter. MoonLake's ...

Barreling toward the loss of exclusivity on its blockbuster oncology therapy Keytruda, Merck & Co. has reportedly offered $3 ...

Donaldson Company (NYSE: DCI) reported its Q3 FY25 results with sales rising 1.3% Y/Y to $940.1M, missing consensus. GAAP net ...